The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Defining Mechanisms Of Androgen Receptor Action That Impede Breast Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$770,619.00
Summary
Androgens (A), commonly considered male hormones, are present in women and may protect them from developing aggressive breast cancer by opposing the cancer-promoting effects of estrogen (E) hormones. We propose that a disturbance in the balance between A and E action in breast cancer worsens the disease and results in a poor outcome for afflicted women. We aim to define how A and E hormones interact in breast cancer, with a view to developing new ways to treat breast cancer and predict outcome.
Nuclear Receptors And Triple Negative Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$681,979.00
Summary
This project will explore the potential for a nuclear receptor known as the thyroid receptor to suppress growth of breast cancer using cell culture models and mouse models. We hope to show that activating the thyroid receptors leads to a reduction in breast cancer growth providing evidence that the thyroid receptor pathway could be targeted for therapy.
Targeted Molecular Therapies And Predictive Biomarkers In A Novel Orthotopic Xenograft Model Of Oesophageal Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$120,253.00
Summary
Oesophageal cancer is the most rapidly increasing malignancy in Western society. This disease often presents in advanced stages with poor response to established medical and surgical therapies. Our aim is to develop a novel mouse model of oesophageal cancer, allowing us to tailor cancer-inhibiting molecular treatments to individual patients by predicting therapeutic success or resistance with the use of cellular markers identified in our animal mode.